Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Altimmune, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

LAS VEGAS--(BUSINESS WIRE)--ALT5 SIGMA CORPORATION (NASDAQ: ALTS)(FRA: 5AR1) (THE COMPANY OR ALT5), A FINTECH AND DIGITAL ASSET TREASURY (DAT) COMPANY SPECIALIZING IN TURNKEY, CRYPTO-RELATED SOLUTIONS FOR INSTITUTIONS AND MERCHANTS, TODAY ANNOUNCED THE APPOINTMENT OF INDUSTRY VETERAN JONATHAN HUGH AS CFO OF THE COMPANY. FOLLOWING ALT5 SIGMA'S RECENTLY ANNOUNCED $1.5 BILLION FINANCING AND THE LAUNCH OF THE COMPANY'S $WLFI TREASURY STRATEGY, WE ARE PLEASED TO ANNOUNCE THE APPOINTMENT OF JONAT.

ALT5 SIGMA CORPORATION APPOINTS JONATHAN HUGH AS CFO

NEW YORK, AUG. 14, 2025 (GLOBE NEWSWIRE) -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS IN ALTIMMUNE, INC. ("ALTIMMUNE" OR THE "COMPANY") (NASDAQ: ALT) OF A CLASS ACTION SECURITIES LAWSUIT.

ALTIMMUNE, INC. SUED FOR SECURITIES LAW VIOLATIONS  INVESTORS SHOULD CONTACT LEVI & KORSINSKY FOR MORE INFORMATION  ALT

NEW YORK , AUG. 13, 2025 /PRNEWSWIRE/ --ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, ANNOUNCES THAT A SHAREHOLDER FILED A CLASS ACTION ON BEHALF OF PURCHASERS OF SECURITIES ALTIMMUNE, INC. (NASDAQ: ALT) BETWEEN AUGUST 10, 2023 AND JUNE 25, 2025 (THE "CLASS PERIOD"). IF YOU WISH TO SERVE AS LEAD PLAINTIFF, YOU MUST MOVE THE COURTNO LATER THAN OCTOBER 6, 2025.

ROSEN LAW FIRM URGES ALTIMMUNE, INC. (NASDAQ: ALT) STOCKHOLDERS TO CONTACT THE FIRM FOR INFORMATION ABOUT THEIR RIGHTS

NEW YORK, AUG. 13, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE, INC. (ALTIMMUNE OR THE COMPANY) (NASDAQ: ALT).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMSON BEHALF OF INVESTORS OF ALTIMMUNE, INC. - ALT

LAS VEGAS--(BUSINESS WIRE)--ALT5 SIGMA CORPORATION (THE COMPANY, OUR OR ALT5) (NASDAQ: ALTS) (FRA:5AR1), A FINTECH SPECIALIZING IN TURNKEY, CRYPTO-RELATED SOLUTIONS FOR INSTITUTIONS AND MERCHANTS, WELCOMES ZACH WITKOFF, CO-FOUNDER AND CEO OF WORLD LIBERTY FINANCIAL, INC. (WLFI), AS CHAIRMAN OF ITS BOARD OF DIRECTORS (THE BOARD), EFFECTIVE UPON THE CLOSING OF ITS PREVIOUSLY ANNOUNCED $1.5 BILLION REGISTERED DIRECT OFFERING AND CONCURRENT PRIVATE PLACEMENT. THE PREVIOUSLY ANNOUNCED FINA.

ALT5 SIGMA CORPORATION APPOINTS ZACH WITKOFF AS CHAIRMAN AND WELCOMES ERIC TRUMP TO BOARD OF DIRECTORS

LAS VEGAS--(BUSINESS WIRE)--ALT5 SIGMA CORPORATION (NASDAQ: ALTS)(FRA: 5AR1) (THE COMPANY OR ALT5) TODAY ANNOUNCED THE CLOSING OF A $1.5 BILLION REGISTERED DIRECT OFFERING (THE REGISTERED DIRECT OFFERING) AND CONCURRENT PRIVATE PLACEMENT (THE PRIVATE PLACEMENT OFFERING AND, TOGETHER WITH THE REGISTERED DIRECT OFFERING, THE OFFERINGS) LED BY WORLD LIBERTY FINANCIAL, INC. (WORLD LIBERTY FINANCIAL). THE GROSS PROCEEDS OF THE OFFERINGS WERE APPROXIMATELY $1.5 BILLION, BEFORE DEDUCTING P.

ALT5 SIGMA CORPORATION ANNOUNCES CLOSING OF $1.5 BILLION REGISTERED DIRECT OFFERING AND CONCURRENT PRIVATE PLACEMENT TO INITIATE WORLD LIBERTY FINANCIAL $WLFI TREASURY STRATEGY

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN ALTIMMUNE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS

SHAREHOLDER ACTION REMINDER: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE

POSITIVE DATA FROM THE IMPACT PHASE 2B TRIAL REINFORCES THE POTENTIAL FOR PEMVIDUTIDE TO BE A HIGHLY DIFFERENTIATED MASH THERAPY PEMVIDUTIDE IS THE FIRST PRODUCT CANDIDATE TO ACHIEVE STATISTICALLY SIGNIFICANT MASH RESOLUTION AND WEIGHT LOSS AT 24 WEEKS NEW DATA FROM THE IMPACT TRIAL DEMONSTRATES POTENTIALLY CLASS-LEADING IMPROVEMENTS IN CORRECTED T1 (CT1), AN IMPORTANT MARKER OF LIVER INFLAMMATION AND FIBROSIS END-OF-PHASE 2 MEETING WITH FDA EXPECTED IN Q4 2025 CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $183.1 MILLION AS OF JUNE 30, 2025 WEBCAST TO BE HELD TODAY, AUGUST 12, 2025, AT 8:30 A.M. ET GAITHERSBURG, MD.

ALTIMMUNE ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATE

NEW YORK, AUG. 11, 2025 (GLOBE NEWSWIRE) -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS IN ALTIMMUNE, INC. ("ALTIMMUNE" OR THE "COMPANY") (NASDAQ: ALT) OF A CLASS ACTION SECURITIES LAWSUIT.

NEW YORK , AUG. 11, 2025 /PRNEWSWIRE/ --POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE, INC. ("ALTIMMUNE" OR THE "COMPANY") (NASDAQ: ALT).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE, INC. - ALT

NEW YORK , AUG. 11, 2025 /PRNEWSWIRE/ -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OF ALTIMMUNE, INC. (NASDAQ: ALT). SHAREHOLDERS WHO PURCHASED SHARES OF ALT DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENT.

SHAREHOLDERS OF ALTIMMUNE, INC. SHOULD CONTACT THE GROSS LAW FIRM BEFORE OCTOBER 6, 2025 TO DISCUSS YOUR RIGHTS - ALT

APPOINTMENT RECOGNIZES MR. DURSO'S EXTENSIVE COMMERCIAL EXPERTISE AS ALTIMMUNE PREPARES FOR PHASE 3 DEVELOPMENT OF PEMVIDUTIDE IN MASH

ALTIMMUNE BOARD OF DIRECTORS APPOINTS JERRY DURSO AS CHAIRMAN

LAS VEGAS--(BUSINESS WIRE)--ALT5 SIGMA CORPORATION (NASDAQ: ALTS)(FRA: 5AR1) (THE COMPANY OR ALT5) TODAY ANNOUNCED THAT IT HAS ENTERED INTO DEFINITIVE AGREEMENTS FOR THE ISSUANCE AND SALE OF AN AGGREGATE OF UP TO 100,000,000 OF ITS SHARES OF COMMON STOCK (OR COMMON STOCK EQUIVALENTS IN LIEU THEREOF) IN A REGISTERED DIRECT OFFERING (THE REGISTERED DIRECT OFFERING) AT A PURCHASE PRICE OF $7.50 PER SHARE. IN A CONCURRENT PRIVATE PLACEMENT (THE PRIVATE PLACEMENT OFFERING AND, TOGETHER WITH.

ALT5 SIGMA CORPORATION ANNOUNCES $1.5 BILLION REGISTERED DIRECT OFFERING AND CONCURRENT PRIVATE PLACEMENT TO INITIATE WORLD LIBERTY FINANCIAL $WLFI TREASURY STRATEGY

NEW YORK, AUG. 09, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE, INC. (ALTIMMUNE OR THE COMPANY) (NASDAQ: ALT).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

NEW YORK , AUG. 8, 2025 /PRNEWSWIRE/ --ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, ANNOUNCES THAT A SHAREHOLDER FILED A CLASS ACTION ON BEHALF OF PURCHASERS OF SECURITIES ALTIMMUNE, INC. (NASDAQ: ALT) BETWEEN AUGUST 10, 2023 AND JUNE 25, 2025 (THE "CLASS PERIOD"). IF YOU WISH TO SERVE AS LEAD PLAINTIFF, YOU MUST MOVE THE COURTNO LATER THAN OCTOBER 6, 2025.

ROSEN LAW FIRM URGES ALTIMMUNE, INC. (NASDAQ: ALT) STOCKHOLDERS WITH LOSSES IN EXCESS OF $100K TO CONTACT THE FIRM FOR INFORMATION ABOUT THEIR RIGHTS

NEW YORK, AUG. 07, 2025 (GLOBE NEWSWIRE) -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OF ALTIMMUNE, INC. (NASDAQ: ALT).

ALTIMMUNE, INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE GROSS LAW FIRM BEFORE OCTOBER 6, 2025 TO DISCUSS YOUR RIGHTS  ALT

NEW YORK--(BUSINESS WIRE)--ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, ANNOUNCES THAT A SHAREHOLDER FILED A CLASS ACTION ON BEHALF OF PURCHASERS OF SECURITIES ALTIMMUNE, INC. (NASDAQ: ALT) BETWEEN AUGUST 10, 2023 AND JUNE 25, 2025. ALTIMMUNE DESCRIBES ITSELF AS A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING TREATMENTS FOR OBESITY, METABOLIC AND LIVER DISEASES. FOR MORE INFORMATION, SUBMIT A FORM, EMAIL ATTORNEY PHILLIP KIM, OR GIVE US A CALL AT 866-767-3653. THE ALLEG.

INVESTORS CAN CONTACT THE LAW FIRM AT NO COST TO LEARN MORE ABOUT RECOVERING THEIR LOSSES

ALTIMMUNE, INC. INVESTORS: PLEASE CONTACT THE PORTNOY LAW FIRM TO RECOVER YOUR LOSSES. OCTOBER 6, 2025 DEADLINE TO FILE LEAD PLAINTIFF MOTION.

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES EXCEEDING $75,000 IN ALTIMMUNE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS.

DEADLINE ALERT: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE

NEW YORK , AUG. 6, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE, INC.("ALTIMMUNE" OR THE "COMPANY") (NASDAQ: ALT).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

GAITHERSBURG, MD., AUG. 05, 2025 (GLOBE NEWSWIRE) -- ALTIMMUNE, INC. (NASDAQ: ALT), A LATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT IT WILL REPORT ITS SECOND QUARTER 2025 FINANCIAL RESULTS ON TUESDAY, AUGUST 12, 2025.

ALTIMMUNE TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON AUGUST 12, 2025

NEW YORK , JULY 31, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE, INC.("ALTIMMUNE" OR THE "COMPANY") (NASDAQ: ALT).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

LAS VEGAS, NEVADA / ACCESS NEWSWIRE / JULY 30, 2025 / ALT5 SIGMA CORPORATION (NASDAQ:ALTS)(FRA:5AR1) ("ALT5" OR THE "COMPANY"), A FINTECH COMPANY DELIVERING BLOCKCHAIN-POWERED PAYMENT AND TRADING INFRASTRUCTURE FOR GLOBAL MERCHANTS AND FINANCIAL INSTITUTIONS, TODAY ANNOUNCED THE SUCCESSFUL INTEGRATION OF ITS INSTITUTIONAL-GRADE ALT5 PRIME FIX API WITH FUNDAMENTAL INTERACTION, A LEADING PROVIDER OF ADVANCED TRADING TECHNOLOGY FOR U.S. FINRA-REGISTERED BROKER-DEALERS AND ALTERNATIVE TRADING SYSTEMS (ATSS). THIS INTEGRATION DELIVERS SEAMLESS FIX-BASED ACCESS TO DIGITAL ASSET MARKETS DIRECTLY INTO THE INFRASTRUCTURE TRUSTED BY THOUSANDS OF BROKER-DEALERS AND TRADING PLATFORMS, REPRESENTING A SIGNIFICANT STEP TOWARD UNIFYING TRADITIONAL CAPITAL MARKETS WITH INSTITUTIONAL-GRADE CRYPTOCURRENCY EXECUTION.

ALT5 SIGMA CORPORATION AND FUNDAMENTAL INTERACTION USHER IN NEW ERA OF INSTITUTIONAL CRYPTO TRADING ACCESS FOR FINRA BROKER-DEALERS

NEW YORK, JULY 28, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE, INC. (ALTIMMUNE OR THE COMPANY) (NASDAQ: ALT). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

NEW YORK , JULY 27, 2025 /PRNEWSWIRE/ -- IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE, INC.("ALTIMMUNE" OR THE "COMPANY") (NASDAQ: ALT).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK, JULY 23, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE, INC. (ALTIMMUNE OR THE COMPANY) (NASDAQ: ALT).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

NEW YORK , JULY 22, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE, INC. ("ALTIMMUNE" OR THE "COMPANY") (NASDAQ: ALT).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

LAS VEGAS, NV / ACCESS NEWSWIRE / JULY 18, 2025 / ALT5 SIGMA CORPORATION (NASDAQ:ALTS)(FRA:5AR1) ("ALT5 OR THE "COMPANY"), A FINTECH COMPANY DELIVERING BLOCKCHAIN-POWERED PAYMENT AND TRADING INFRASTRUCTURE FOR GLOBAL MERCHANTS AND FINANCIAL INSTITUTIONS, TODAY WELCOMED THE SIGNING OF THE GENIUS ACT, A LANDMARK U.S. LAW ESTABLISHING A REGULATORY FRAMEWORK FOR STABLECOIN ISSUANCE AND OVERSIGHT. "WE BELIEVE THIS LEGISLATION MARKS A TURNING POINT," SAID PETER TASSIOPOULOS, CEO OF ALT5 SIGMA.

ALT5 SIGMA SIGNALS READINESS AS U.S. STABLECOIN LEGISLATION PASSES INTO LAW

NEW YORK, JULY 18, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE, INC. (ALTIMMUNE OR THE COMPANY) (NASDAQ: ALT).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

NEW YORK , JULY 17, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE, INC.("ALTIMMUNE" OR THE "COMPANY") (NASDAQ: ALT).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK, JULY 14, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE, INC. (ALTIMMUNE OR THE COMPANY) (NASDAQ: ALT). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

GAITHERSBURG, MD., JULY 09, 2025 (GLOBE NEWSWIRE) -- ALTIMMUNE, INC. (NASDAQ: ALT), A LATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL PEPTIDE-BASED THERAPEUTICS FOR LIVER AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THAT IT HAS ENROLLED THE FIRST PATIENT IN THE RESTORE PHASE 2 TRIAL EVALUATING THE EFFICACY AND SAFETY OF PEMVIDUTIDE IN SUBJECTS WITH ALCOHOL-ASSOCIATED LIVER DISEASE (ALD). PEMVIDUTIDE IS A NOVEL, INVESTIGATIONAL GLP-1/GLUCAGON DUAL RECEPTOR AGONIST IN DEVELOPMENT FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), ALCOHOL USE DISORDER (AUD), ALD AND OBESITY.

ALTIMMUNE ANNOUNCES INITIATION OF RESTORE PHASE 2 TRIAL EVALUATING THE EFFICACY AND SAFETY OF PEMVIDUTIDE IN ALCOHOL-ASSOCIATED LIVER DISEASE (ALD)

NEW YORK , JULY 7, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE, INC. ("ALTIMMUNE" OR THE "COMPANY") (NASDAQ: ALT).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK, JULY 03, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE, INC. (ALTIMMUNE OR THE COMPANY) (NASDAQ: ALT).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

NEW YORK , JULY 2, 2025 /PRNEWSWIRE/ --POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE, INC. ("ALTIMMUNE" OR THE "COMPANY") (NASDAQ: ALT).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

LAS VEGAS, NV / ACCESS NEWSWIRE / JULY 1, 2025 / ALT5 SIGMA CORPORATION (NASDAQ:ALTS)(FRA:5AR1) ("ALT5 OR THE "COMPANY"), A FINTECH COMPANY PROVIDING BLOCKCHAIN-POWERED PAYMENT AND TRADING INFRASTRUCTURE FOR GLOBAL MERCHANTS AND FINANCIAL INSTITUTIONS, HAS ANNOUNCED TODAY THAT IT HAS BEEN ADDED AS A MEMBER OF THE RUSSELL MICROCAP GROWTH, RUSSELL 3000E AND RUSSELL 3000E GROWTH INDEXES, AS PART OF THE 2025 RUSSELL INDEXES RECONSTITUTION. THE COMPANY HAD PREVIOUSLY BEEN INCLUDED IN THE RUSSEL MICROCAP INDEX SINCE JUNE OF 2024.

ALT5 SIGMA CORPORATION ADDED TO THE RUSSELL MICROCAP GROWTH INDEX, RUSSELL 3000E INDEX AND RUSSELL 3000E GROWTH INDEX

NEW YORK, JULY 01, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE, INC. (ALTIMMUNE OR THE COMPANY) (NASDAQ: ALT).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

NEW YORK , JUNE 27, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE, INC. ("ALTIMMUNE" OR THE "COMPANY") (NASDAQ: ALT).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

FIRST PRODUCT CANDIDATE TO DEMONSTRATE SIGNIFICANT MASH EFFECTS AND WEIGHT LOSS AT 24 WEEKS TRIAL MET ITS PRIMARY ENDPOINT WITH STATISTICALLY SIGNIFICANT MASH RESOLUTION WITHOUT WORSENING OF FIBROSIS IN UP TO 59.1% OF PARTICIPANTS IN AN ITT ANALYSIS FIBROSIS IMPROVEMENT WITHOUT WORSENING OF MASH IN UP TO 34.5% OF PARTICIPANTS IN AN ITT ANALYSIS SUPPLEMENTAL AI-BASED ANALYSIS DEMONSTRATED STATISTICALLY SIGNIFICANT REDUCTIONS IN LIVER FIBROSIS AT 24 WEEKS WEIGHT LOSS OF UP TO 6.2% AT 24 WEEKS WITH NO PLATEAUING POTENTIALLY BEST-IN-CLASS TOLERABILITY, WITH LESS THAN 1% TREATMENT DISCONTINUATIONS DUE TO ADVERSE EVENTS IN PEMVIDUTIDE-TREATED PARTICIPANTS CONFERENCE CALL TO BE HELD ON JUNE 26, 2025 AT 8:30 AM ET GAITHERSBURG, MD., JUNE 26, 2025 (GLOBE NEWSWIRE) -- ALTIMMUNE, INC. (NASDAQ: ALT), A LATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL PEPTIDE-BASED THERAPEUTICS FOR LIVER AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED POSITIVE TOPLINE RESULTS FROM THE IMPACT PHASE 2B TRIAL OF PEMVIDUTIDE IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH).

ALTIMMUNE ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE IMPACT PHASE 2B TRIAL OF PEMVIDUTIDE IN THE TREATMENT OF MASH

COMPANY TO HOST INVESTOR WEBCAST ON THURSDAY, JUNE 26, 2025, AT 8:30 AM E.T. COMPANY TO HOST INVESTOR WEBCAST ON THURSDAY, JUNE 26, 2025, AT 8:30 AM E.T.

ALTIMMUNE TO ANNOUNCE TOPLINE 24 WEEK RESULTS FROM ITS IMPACT PHASE 2B TRIAL OF PEMVIDUTIDE IN THE TREATMENT OF MASH ON THURSDAY, JUNE 26

GAITHERSBURG, MD., JUNE 13, 2025 (GLOBE NEWSWIRE) -- ALTIMMUNE, INC. (NASDAQ: ALT), A LATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL PEPTIDE-BASED THERAPEUTICS FOR LIVER AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED AN ORAL PRESENTATION AND THREE POSTER PRESENTATIONS ON PEMVIDUTIDE AT THE AMERICAN DIABETES ASSOCIATION'S (ADA) 85TH SCIENTIFIC SESSIONS, TO BE HELD IN CHICAGO, IL FROM JUNE 20-23, 2025.

ALTIMMUNE ANNOUNCES MULTIPLE PRESENTATIONS AT UPCOMING AMERICAN DIABETES ASSOCIATION'S SCIENTIFIC SESSIONS

LAS VEGAS, NV / ACCESS NEWSWIRE / JUNE 11, 2025 / ALT5 SIGMA CORPORATION (NASDAQ:ALTS)(FRA:5AR1), A FINTECH SPECIALIZING IN TURNKEY, CRYPTO-RELATED SOLUTIONS FOR INSTITUTIONS AND MERCHANTS, IS PLEASED TO ANNOUNCE ITS PARTICIPATION IN IFX EXPO INTERNATIONAL, TAKING PLACE JUNE 11, 2025, IN LIMASSOL, CYPRUS. ALT5 SIGMA WILL EXHIBIT AT BOOTH #97 AND IS PROUD TO BE BACK FOR A SECOND YEAR AT THIS FLAGSHIP EVENT.

Altimmune, Inc.

ALT

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Altimmune, Inc.

ALT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ALT